Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

-2.33 (-1.64%)
(As of 11:51 AM ET)
Today's Range
50-Day Range
52-Week Range
146,292 shs
Average Volume
823,569 shs
Market Capitalization
$14.09 billion
P/E Ratio
Dividend Yield
Price Target

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
4.4% Upside
$148.96 Price Target
Short Interest
1.82% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.80mentions of Neurocrine Biosciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$26.88 M Sold Last Quarter
Proj. Earnings Growth
From $4.17 to $6.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Medical Sector

56th out of 914 stocks

Biological Products, Except Diagnostic Industry

5th out of 153 stocks

NBIX stock logo

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

NBIX Stock News Headlines

See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
24 Analysts


Net Income
$249.70 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$2.59 per share
Book Value
$22.72 per share


Free Float
Market Cap
$14.36 billion
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 66)
    CEO & Director
    Comp: $2.05M
  • Mr. Matthew C. Abernethy (Age 44)
    Chief Financial Officer
    Comp: $1.06M
  • Dr. Jude Onyia Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $1.22M
  • Mr. Kyle W. Gano Ph.D. (Age 51)
    Chief Business Development & Strategy Officer
    Comp: $990.12k
  • Dr. Eiry Wyn Roberts M.D. (Age 60)
    Chief Medical Officer
    Comp: $1.12M
  • Jane Sorensen
    Head of Investor Relations
  • Mr. Darin M. Lippoldt Esq. (Age 58)
    Chief Legal Officer & Corporate Secretary
    Comp: $921.01k
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 58)
    Chief Human Resources Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 59)
    Chief Commercial Officer
    Comp: $805k
  • Mr. David Warren Boyer (Age 44)
    Chief Corporate Affairs Officer

NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price target for 2024?

24 analysts have issued 12-month price objectives for Neurocrine Biosciences' shares. Their NBIX share price targets range from $100.00 to $216.00. On average, they expect the company's share price to reach $148.96 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 on January 1st, 2024. Since then, NBIX shares have increased by 8.3% and is now trading at $142.70.
View the best growth stocks for 2024 here

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our NBIX earnings forecast

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday, February, 7th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a trailing twelve-month return on equity of 17.45%. The firm's revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.87%), Bellevue Group AG (2.04%), Janus Henderson Group PLC (1.37%), Bank of New York Mellon Corp (0.93%), Jacobs Levy Equity Management Inc. (0.71%) and Allspring Global Investments Holdings LLC (0.51%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 5/20/2024 by Staff

From Our Partners